Skip to main content

Research News

Pharma Courses
  • Lynparza demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial

    Updated results from the OlympiA Phase III trial showed AstraZeneca and MSDs Lynparza olaparib demonstrated sustained, clinically meaningful improvements in overall survival , invasive disease-free survival IDFS and distant disease-free survival DDFS at six years for patients with germline BRCA-mutated gBRCAm HER2-negative high-risk early breast cancer.
  • Antidepressants may act in gut to reduce depression and anxiety

    Most of us have experienced the effects of moods and emotions on our gastrointestinal tract, from “butterflies” in the stomach caused by nervousness to a loss of appetite when we’re feeling blue.

  • A new class of antivirals could help prevent future pandemics
    The arrival of Paxlovid in December 2021 marked another turning point in the COVID-19 pandemic—an effective antiviral that has since successfully treated millions. But like many antivirals before it, scientists know that at some point, Paxlovid is likely to lose some efficacy due to drug resistance. Researchers working to stay ahead of such emerging threats have now identified a wholly new way to treat SARS-CoV-2 infections—work that may have even broader implications.
  • Identifying a proliferating repairman for tissue in damaged lungs

    Veins in the lungs, or pulmonary veins, play a critical role not only in lung functioning but also in maintaining sufficient oxygen in tissue throughout the body. When a person sustains pulmonary injury from an illness like influenza or COVID, repair of blood vessels and the creation of new ones is vital to meet oxygen demands; however, research in these areas remains underexplored.

  • Updated Hep B Vaccine More Effective for People with HIV

    A newer vaccine against hepatitis B virus was clearly superior to an older vaccine type in inducing a protective antibody response among people living with HIV who didn’t respond to prior vaccination, according to the results of an international study led by a Weill Cornell Medicine investigator.

  • Stanford scientists transform ubiquitous skin bacterium into a topical vaccine

    Imagine a world in which a vaccine is a cream you rub onto your skin instead of a needle a health care worker pushes into your one of your muscles. Even better, it’s entirely pain-free and not followed by fever, swelling, redness or a sore arm. No standing in a long line to get it. Plus, it’s cheap.

  • Cancer fingerprint can improve early detection

    Different types of cancer have unique molecular ‘fingerprints’ which are detectable in early stages of the disease and can be picked up with near-perfect accuracy by small, portable scanners in just a few hours, according to a study published today in the journal Molecular Cell.

  • NIH Study Finds Tecovirimat Was Safe but Did Not Improve Mpox Resolution or Pain

    The antiviral drug tecovirimat did not reduce the time to lesion resolution or have an effect on pain among adults with mild to moderate clade II mpox and a low risk of developing severe disease, according to an interim data analysis from the international clinical trial called the Study of Tecovirimat for Mpox (STOMP). There were no safety concerns associated with tecovirimat.

  • New drug tested to reduce side effect of ‘half-matched’ stem cell transplants
    Stem cell transplantation, using devices like the one shown here, is used to treat several types of blood cancers, but carries the risk of a life-threatening side effect called graft-versus-host disease. Results from a clinical trial conducted by researchers at WashU Medicine showed adding the investigational drug itacitinib to standard care for half-matched stem cell transplantation may reduce rates of the disease, in which the donor’s stem cells attack the patient’s healthy tissues.
  • Wearable devices can help predict five year risk of falls for people with Parkinson’s Disease
    Falls are a common problem for people living with Parkinson’s. A recent review estimated that some 60% of all people living with PD have experienced at least one fall. These can lead to injury and hospitalisation, as well as reduced mobility, quality of life, and life expectancy.
Subscribe to Research News